Oppenheimer has launched its coverage of BridgeBio Pharma (NASDAQ:BBIO) with a Perform recommendation, noting "substantial challenges" to the company as it races to market its late-stage assets, ...
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), Wednesday announced positive data from the CANOPY clinical program evaluating Voxzogo in children with achondroplasia, a rare genetic skeletal ...
Predictably, weekly vs. daily subcutaneous injections made a big difference in the achondroplasia space, where shares of Copenhagen, Denmark-based Ascendis Pharma A/S (NASDAQ:ASND) closed Sept. 16 at ...
Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.
(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...